Advertisement

18F-Fluoride: Benign Bone Disease

  • Kalevi Kairemo
  • Homer A. Macapinlac
Chapter
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)

Abstract

Multiple studies support the application of NaF-PET to assess benign osseous conditions. In particular, bone turnover can be measured from NaF uptake to diagnose osteoporosis. Several studies have evaluated the efficacy of bisphosphonates and their lasting effects as treatment for osteoporosis using bone turnover measured by NaF-PET [1]. Additionally, NaF uptake in vessels tracks calcification in the plaques at the molecular level, which is relevant to coronary artery disease (presented in Chaps.  10 and  11). Also, NaF-PET imaging of diseased joints is able to project disease progression in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Further studies suggest potential use of NaF-PET in domains such as back pain, osteosarcoma, stress-related fracture, and bisphosphonate-induced osteonecrosis of the jaw. The critical role of NaF-PET in disease detection and characterization of many musculoskeletal disorders has been clearly demonstrated in the literature, and these methods will become more widespread in the future. The data from PET imaging are quantitative in nature, and as such, it adds a major dimension to assessing disease activity.

References

  1. 1.
    Rohren EM, Macapinlac HA. Spectrum of benign bone conditions on NaF-PET. Semin Nucl Med. 2017;47:392–6.CrossRefGoogle Scholar
  2. 2.
    Rohren EM, Etchebehere EC, Araujo JC, et al. Determination of skeletal tumor burden on 18F-fluoride PET/CT. J Nucl Med. 2015;56:1507–12.CrossRefGoogle Scholar
  3. 3.
    Uchida K, Nakajima H, Miyazaki T, et al. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study. J Nucl Med. 2009;50:1808–14.CrossRefGoogle Scholar
  4. 4.
    Kobayashi N, Inaba Y, Yukizawa Y, et al. Use of 18F-fluoride positron emission tomography as a predictor of hip osteoarthritis progression. Mod Rheumatol. 2015;25:925–30.CrossRefGoogle Scholar
  5. 5.
    Watanabe T, Takase-Minegishi K, Ihata A, et al. 18F-FDG and 18F-NaF PET/CT demonstrate coupling of inflammation and accelerated bone turnover in rheumatoid arthritis. Mod Rheumatol. 2016;26:180–7.CrossRefGoogle Scholar
  6. 6.
    Idolazzi L, Salgarello M, Gatti D, et al. 18F-fluoride PET/CT for detection of axial involvement in ankylosing spondylitis: correlation with disease activity. Ann Nucl Med. 2016;30:430–4.CrossRefGoogle Scholar
  7. 7.
    Buchbender C, Ostendorf B, Ruhlmann V, et al. Hybrid 18F-labeled fluoride positron emission tomography/magnetic resonance (MR) imaging of the sacroiliac joints and the spine in patients with axial spondyloarthritis: a pilot study exploring the link of MR bone pathologies and increased osteoblastic activity. J Rheumatol. 2015;42:1631–7.CrossRefGoogle Scholar
  8. 8.
    Grant FD. 18F-fluoride PET and PET/CT in children and young adults. PET Clin. 2014;9:287–97.CrossRefGoogle Scholar
  9. 9.
    Shim JJ, Lee JW, Jeon MH, et al. Recurrent surgical site infection of the spine diagnosed by dual 18F-NaF-bone PET/CT with early-phase scan. Skelet Radiol. 2016;45:1313–6.CrossRefGoogle Scholar
  10. 10.
    Kumar R, Kumar R, Kumar V, et al. Comparative analysis of dual-phase 18F-fluoride PET/CT and three phase bone scintigraphy in the evaluation of septic (or painful) hip prostheses: a prospective study. J Orthop Sci. 2016;21:205–10.CrossRefGoogle Scholar
  11. 11.
    Rauscher I, Beer AJ, Schaeffeler C, et al. Evaluation of 18F-fluoride PET/MR and PET/CT in patients with foot pain of unclear cause. J Nucl Med. 2015;56:430–5.CrossRefGoogle Scholar
  12. 12.
    Kim JY, Choi YY, Kim YH, Park SB, Jeong MA. Role of (18)F-fluoride PET/CT over dual-phase bone scintigraphy in evaluation and management of lesions causing foot and ankle pain. Ann Nucl Med. 2015;29:302–12.CrossRefGoogle Scholar
  13. 13.
    Papadakis GZ, Jha S, Bhattacharyya T, et al. 18F-NaF PET/CT in extensive melorheostosis of the axial and appendicular skeleton with soft-tissue involvement. Clin Nucl Med. 2017;42:537–9.CrossRefGoogle Scholar
  14. 14.
    Cucchi F, Simonsen L, Abild-Nielsen AG, Broholm R. 18F-sodium fluoride PET/CT in Paget disease. Clin Nucl Med. 2017;42:553–4.CrossRefGoogle Scholar
  15. 15.
    Papadakis GZ, Millo C, Bagci U, Blau J, Collins MT. 18F-NaF and 18F-FDG PET/CT in Gorham-Stout disease. Clin Nucl Med. 2016;41:884–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Kalevi Kairemo
    • 1
    • 2
  • Homer A. Macapinlac
    • 2
  1. 1.Department of Nuclear Medicine and Molecular RadiotherapyDocrates Cancer CenterHelsinkiFinland
  2. 2.Department of Nuclear MedicineUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations